Market closedADR
Autolus Therapeutics/$AUTL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Autolus Therapeutics
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
Ticker
$AUTL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
467
Website
AUTL Metrics
BasicAdvanced
$503M
-
-$1.16
2.04
-
Price and volume
Market cap
$503M
Beta
2.04
52-week high
$2.13
52-week low
$1.68
Financial strength
Current ratio
13.685
Quick ratio
13.347
Long term debt to equity
62.395
Total debt to equity
63.143
Interest coverage (TTM)
-3.11%
Management effectiveness
Return on assets (TTM)
-22.11%
Return on equity (TTM)
-82.20%
Valuation
Price to revenue (TTM)
43.478
Price to book
1.05
Price to tangible book (TTM)
1.05
Price to free cash flow (TTM)
-2.134
Growth
Revenue change (TTM)
82.71%
Earnings per share change (TTM)
15.66%
3-year revenue growth (CAGR)
58.09%
3-year earnings per share growth (CAGR)
-19.33%
AUTL News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Autolus Therapeutics stock?
Autolus Therapeutics (AUTL) has a market cap of $503M as of March 14, 2025.
What is the P/E ratio for Autolus Therapeutics stock?
The price to earnings (P/E) ratio for Autolus Therapeutics (AUTL) stock is 0 as of March 14, 2025.
Does Autolus Therapeutics stock pay dividends?
No, Autolus Therapeutics (AUTL) stock does not pay dividends to its shareholders as of March 14, 2025.
When is the next Autolus Therapeutics dividend payment date?
Autolus Therapeutics (AUTL) stock does not pay dividends to its shareholders.
What is the beta indicator for Autolus Therapeutics?
Autolus Therapeutics (AUTL) has a beta rating of 2.04. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.